Skip to main content
Journal cover image

Hydrazine sulfate in cancer patients with weight loss. A placebo-controlled clinical experience.

Publication ,  Journal Article
Chlebowski, RT; Bulcavage, L; Grosvenor, M; Tsunokai, R; Block, JB; Heber, D; Scrooc, M; Chlebowski, JS; Chi, J; Oktay, E
Published in: Cancer
February 1, 1987

Hydrazine sulfate was evaluated using 24-hour dietary recalls and body weight determinations before and after 30 days of either placebo or hydrazine (60 mg, 3 times/d) oral administration in 101 heavily pretreated cancer patients with weight loss. After 1 month, 83% of hydrazine and only 53% of placebo patients completing repeat evaluation maintained or increased their weight (P less than 0.05). In addition, appetite improvement was more frequent in the hydrazine group (63% versus 25%, P less than 0.05). Although caloric intake was only slightly greater in hydrazine-treated patients, an increased caloric intake was more commonly associated with weight gain in patients receiving hydrazine compared with those receiving placebo (81% versus 53%, respectively). Hydrazine toxicity was mild, with 71% of patients reporting no toxic effects. Hydrazine sulfate circulatory levels were obtained from a subset of 14 patients who completed 30 days of treatment, with a single sample obtained in the morning at least 9 hours after the last dose. Mean maintenance hydrazine sulfate levels, determined using a spectrofluorometric assay, ranged from 0 to 89 ng/ml (mean 45 +/- 16 ng/ml). These data, which demonstrate an association between 1 month of hydrazine sulfate administration and body weight maintenance in patients with cancer, suggest future clinical trials of hydrazine sulfate are indicated to definitively assess its long-term impact on important clinical outcome parameters in defined cancer populations.

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer

DOI

ISSN

0008-543X

Publication Date

February 1, 1987

Volume

59

Issue

3

Start / End Page

406 / 410

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Neoplasms
  • Hydrazines
  • Humans
  • Energy Intake
  • Drug Tolerance
  • Cachexia
  • Body Weight
  • Appetite
  • 4206 Public health
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chlebowski, R. T., Bulcavage, L., Grosvenor, M., Tsunokai, R., Block, J. B., Heber, D., … Oktay, E. (1987). Hydrazine sulfate in cancer patients with weight loss. A placebo-controlled clinical experience. Cancer, 59(3), 406–410. https://doi.org/10.1002/1097-0142(19870201)59:3<406::aid-cncr2820590309>3.0.co;2-w
Chlebowski, R. T., L. Bulcavage, M. Grosvenor, R. Tsunokai, J. B. Block, D. Heber, M. Scrooc, J. S. Chlebowski, J. Chi, and E. Oktay. “Hydrazine sulfate in cancer patients with weight loss. A placebo-controlled clinical experience.Cancer 59, no. 3 (February 1, 1987): 406–10. https://doi.org/10.1002/1097-0142(19870201)59:3<406::aid-cncr2820590309>3.0.co;2-w.
Chlebowski RT, Bulcavage L, Grosvenor M, Tsunokai R, Block JB, Heber D, et al. Hydrazine sulfate in cancer patients with weight loss. A placebo-controlled clinical experience. Cancer. 1987 Feb 1;59(3):406–10.
Chlebowski, R. T., et al. “Hydrazine sulfate in cancer patients with weight loss. A placebo-controlled clinical experience.Cancer, vol. 59, no. 3, Feb. 1987, pp. 406–10. Pubmed, doi:10.1002/1097-0142(19870201)59:3<406::aid-cncr2820590309>3.0.co;2-w.
Chlebowski RT, Bulcavage L, Grosvenor M, Tsunokai R, Block JB, Heber D, Scrooc M, Chlebowski JS, Chi J, Oktay E. Hydrazine sulfate in cancer patients with weight loss. A placebo-controlled clinical experience. Cancer. 1987 Feb 1;59(3):406–410.
Journal cover image

Published In

Cancer

DOI

ISSN

0008-543X

Publication Date

February 1, 1987

Volume

59

Issue

3

Start / End Page

406 / 410

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Neoplasms
  • Hydrazines
  • Humans
  • Energy Intake
  • Drug Tolerance
  • Cachexia
  • Body Weight
  • Appetite
  • 4206 Public health